@natcomms.nature.comResults from an open label, multicenter phase I #trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of #ASTX660 in combination with the anti-PD-1 antibody #pembrolizumab for solid #tumors doi.org/10.1038/s414...
@pbtscience.bsky.socialThank you to @innovativeresearch.bsky.social for providing support for this episode!
#cancer #tumors #physics #scicomm #sciencecommunication
@notredame.bsky.social @phdmarie.bsky.social
@deadpetvet.bsky.socialHappy #MicroscopeMonday 🔬ft a gastric neuroendocrine tumor in a bearded dragon! Bearded dragons have a high prevalence of this tumor that originates primarily in the pyloric mucosa, are highly aggressive with consistent hepatic metastasis and intravascular tumor emboli.
@bocascientificinc.bsky.socialImmunotherapy has been found to have limited success against pediatric #tumors, due to #Tcells becoming "exhausted". @stjuderesearch.bsky.social found #gene ZMYND8 is a major regulator of CD8+ T-cell exhaustion, and removing the gene improves antitumor response.
www.nature.com/articles/s41...
@mdpipharma.bsky.social🎯 Can #cancer cells #self-target? PC3 cells labeled with [89Zr]Zr-oxine showed high uptake in PC3 tumors but not 4T1 #tumors—demonstrating homotypic targeting for #imaging & therapy.
📌 www.mdpi.com/1999-4923/17...
#HomotypicTargeting #CancerResearch #PETImaging
@cib-csic.bsky.socialExploring and exploiting the vasculature in brain #tumors
Leire Bejarano Bosque,
BioGipuzkoa Health Research Institute
📅Sep 24
⏰12h
📍CIB-CSIC
@sroa-radonc.bsky.socialThe Mayo Clinic reported promising patient results for minibeam radiotherapy, which splits a standard beam into half-millimeter beamlets, creating high-dose "peaks" and low-dose "valleys" where healthy tissue can recover. shorturl.at/n2l4n #radiotherapy #oncology #tumors #sarcoma #skincancer
@z9nc.bsky.socialneed to get my #tumors removed
@cib-csic.bsky.socialExploring and exploiting the vasculature in brain #tumors
Leire Bejarano Bosque,
BioGipuzkoa Health Research Institute
📅Sep 24
⏰12h
📍CIB-CSIC
@tamedoncol.bsky.socialAre T-cell engagers ready to reshape the #treatment of solid #tumors?
This review summarizes current evidence on their safety profile and AE management, key challenges in clinical practice.
journals.sagepub.com/doi/full/10....
#TAMO #oncology
